CEO turned informant: How the FDA built a case against executives promising cheap medications
The FDA's unprecedented criminal case against an alternative funding program hinged on the cooperation of a peer CEO, according to a court record.
PublisherCNBC
Categorymarkets
Published2026-11-18T21:07:14Z
Indexed9h ago
More from CNBC
- Walmart hikes outlook as CEO tells CNBC retailer aims to keep prices low despite soaring fuel costs36m ago
- Trump bought Nvidia, Palantir, SpaceX in September as federal deals, White House ties grew51m ago
- Kraken parent's acquisition of Tribe Capital flags new chapter in evolution of crypto exchanges1h ago
- Trump, Xi, Putin said they plan to boost oil production, revamp UN after trilateral talks3h ago
Latest in markets
- Walmart hikes outlook as CEO tells CNBC retailer aims to keep prices low despite soaring fuel costsCNBC · 36m ago
- Why Micron, Broadcom and other AI stocks have given up their gainsMarketWatch · 51m ago
- The surprising reason the U.S. economy is speeding up — and might have more room to runMarketWatch · 1h ago
- Elon Musk becomes the latest tech billionaire to make a peace offering to Democrats after the midtermsMarketWatch · 1h ago
- Forget data centers. The next great AI stocks are hiding in plain sight in these four sectors.MarketWatch · 2h ago
FinancePulse indexes headlines and short summaries from 20 institutional publishers. This page does not republish the full article — all rights belong to CNBC.